ØTarget-driven intervention aimed at multiple risk factors in non-diabetic
patients with MetS is safe and substantially offsets MetS component
features and both biochemical and ultrasonographic evidence of NAFLD.
ØThese effects could be related to hypolipidaemic
drug treatment and
the administration of orlistat,
metformin and ACEIs as well as the
reduction in
hsCRP, waist circumference, BW, TGs, LDL-C,
fasting
glucose, systolic BP and total cholesterol.
Ø
ØThe atorvastatin-fenofibrate
combination and atorvastatin monotherapy
were more effective than fenofibrate alone in
reducing both biochemical
and ultrasonographic evidence of NAFLD despite the fact that all the
other
potentially beneficial treatments
were equally administered
in the fenofibrate group.